Impact of carboplatin schedule on pCR in a modified KEYNOTE-522 regimen with dose-dense AC for triple negative breast cancer
In this single-center analysis, every three-week carboplatin dosing followed by ddAC in a modified KEYNOTE-522 regimen provides higher pCR rates at the time of surgery. Patients who received weekly carboplatin dosing experienced more iHSR. These findings strongly warrant additional studies to determine the relationship of carboplatin dosing to TNBC outcomes.
Authors
- Stephanie Collins
- Eric McLaughlin (ORCID: https://orcid.org/0000-0003-2200-5905)
- Allison Reed
- Dionisia Quiroga (ORCID: https://orcid.org/0000-0003-3388-7069)
- Kennedi Satterfield
- Michael Berger (ORCID: https://orcid.org/0000-0003-0214-6233)
Institutions
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- The Ohio State University Wexner Medical Center (US)
- The Ohio State University (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf372
- Primary Topic
- Breast Cancer Treatment Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00